Facebook Linkedin Tumblr Twitter
Home Blog Page 20

Citius Pharmaceuticals, Inc. (OTCMKTS:CTXR) Files An 8-K Submission of Matters to a Vote of Security Holders

By
ME Staff 8-k
-

Citius Pharmaceuticals, Inc. (OTCMKTS:CTXR) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07 (the “Original Form 8-K”) the voting results for the proposals submitted to stockholders at the Company’s Special Meeting of Stockholders (the “Special Meeting”), held on May 24, 2021. The Special Meeting was adjourned until June 21, 2021 with respect to Proposal 1, as set forth in the Company’s definitive proxy statement on Schedule 14A, dated April 12, 2021, for the Special Meeting (the “Definitive Proxy Statement”), to approve an amendment to the Company’s Articles of Incorporation to increase the number of authorized shares of capital stock from 210,000,000 to 410,000,000 shares and the authorized number of common shares from 200,000,000 to 400,000,000 (the “Increase”). This Current Report on Form 8-K/A amends and supplements the Original Form 8-K to disclose the voting results with respect to Proposal 1 voted on at the reconvened portion of the Special Meeting held on June 21, 2021. No other changes have been made to the Original Form 8-K.

Item 3.03 – Material Modification to Rights of Security Holders.

To the extent required by Item 3.03 of Form 8-K, the information regarding the Increase described in Items 5.03 and 5.07 of this Current Report on Form 8-K/A is incorporated by reference in this Item 3.03.

Item 5.03 – Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

On June 21, 2021, the Company reconvened and concluded the Special Meeting. As previously reported in the Original Form 8-K, the Company’s stockholders voted on, and approved two proposals at the Special Meeting, including a proposal to adjourn the Special Meeting in the event that there were insufficient votes to approve the Increase. Following approval of the adjournment proposal, the Special Meeting was adjourned until June 21, 2021 in order to allow the Company’s stockholders more time to consider and approve the Increase. Following approval of the Increase at the reconvened Special Meeting, the Increase became effective on June 21, 2021. The description of the amendment to effectuate the Increase is qualified in its entirety by reference to the full text of the Certificate of Amendment for the Increase, a copy of which is included hereto as Exhibit 3.1 and incorporated by reference herein.

Item 5.07. Submission of Matters to a Vote of Security Holders.

We reconvened the Special Meeting at 8:00 a.m., Eastern time, on June 21, 2021. At the reconvened Special Meeting, stockholders approved an amendment to our Articles of Incorporation to increase the authorized number of shares from 210,000,000 to 410,000,000 and the authorized number of common shares from 200,000,000 to 400,000,000. The vote for such approval was 68,411,111 shares for, 13,230,161 shares against, 824,790 shares abstaining, and no broker non-votes.

Item 9.01 – Financial Statement and Exhibits.

(d)       Exhibits

Exhibit No. Description
3.1 Certificate of Amendment to the Articles of Incorporation of Citius Pharmaceuticals, Inc. dated June 21, 2021.


Citius Pharmaceuticals, Inc. Exhibit
EX-3.1 2 ea143024ex3-1_citiuspharma.htm CERTIFICATE OF AMENDMENT TO THE ARTICLES OF INCORPORATION OF CITIUS PHARMACEUTICALS,…
To view the full exhibit click here

About Citius Pharmaceuticals, Inc. (OTCMKTS:CTXR)

Citius Pharmaceuticals, Inc., formerly Trail One, Inc., is a pharmaceutical company engaged in developing and commercializing therapeutic products. The Company focuses on developing formulations to manage the delivery and compliance of approved drugs. The Company offers Suprenza, an orally disintegrating tablet and an obesity drug that can be administered with water or dissolved on tongue. The Company also focuses on development of its product candidate, Hydrocortisone-Lidocaine Cream, which is in Phase II study. Its Hydrocortisone-Lidocaine Cream is used to provide anti-inflammatory and anesthetic relief to persons suffering from grade I and II hemorrhoids. Citius Pharmaceuticals, LLC is its subsidiary. The Company has not generated any revenues.

Story continues below

STAFFING 360 SOLUTIONS, INC. (NASDAQ:STAF) Files An 8-K Submission of Matters to a Vote of Security Holders

By
ME Staff 8-k
-

STAFFING 360 SOLUTIONS, INC. (NASDAQ:STAF) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders.

A special meeting (the “Special Meeting”) of the stockholders of Staffing 360 Solutions, Inc. (the “Company”) was held on June 21, 2021. The matter described below was submitted to a vote of the Company’s stockholders at the Special Meeting. The proposal is described in detail in the Company’s definitive proxy statement filed with the U.S. Securities and Exchange Commission on May 24, 2021 (the “Proxy Statement”).

Proposal 1. A proposal to approve the amendment to the Company’s amended and restated certificate of incorporation to effect, at the discretion of the Company’s board of directors but prior to the Company’s 2021 annual stockholder meeting, a reverse stock split of all of the outstanding shares of the Company’s common stock, par value $0.00001 per share, at a ratio in the range of 1-for-2 to 1-for-20, such ratio to be determined by the Company’s board of directors and included in a public announcement.

The Company’s stockholders approved Proposal 1, with the following voting results:

For Against Abstentions Broker Non-Votes
28,737,407 4,417,710 49,649 –

For more information about the foregoing proposal, see the Proxy Statement, the relevant portions of which are incorporated herein by reference. The results reported above are final voting results. No other matters were considered or voted upon at the meeting.


About STAFFING 360 SOLUTIONS, INC. (NASDAQ:STAF)

Staffing 360 Solutions, Inc. operates in the staffing sector. The Company is engaged in the execution of a global buy-and-build strategy through the acquisition of domestic and international staffing organizations in the United States and the United Kingdom. Its targeted consolidation model is focused on the finance and accounting, administrative, engineering and information technology (IT) staffing space.

Story continues below

Verde Resources, Inc. (OTCMKTS:VRDR) Files An 8-K Entry into a Material Definitive Agreement

By
ME Staff 8-k
-

Verde Resources, Inc. (OTCMKTS:VRDR) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01 Entry into a Material Definitive Agreement

On June 17, 2021, Verde Resources, Inc. (the “Company”), through its indirect subsidiary Bio Resources Limited (“BRL”), a company incorporated under the laws of the Labuan, entered into a Shares Sale Agreement with Global Renewables Sdn Bhd (“Global Renewables”), a company incorporated under the laws of the Malaysia, to acquire the entire issued and paid-up share capital of Global Renewables. Under the terms of the Shares Sale Agreement, the consideration for the acquisition shall be satisfied in full by the payment of Malaysia Ringgit MYR 25,000 upon the execution of the Shares Sale Agreement.

On June 18, 2021, the Company, through its wholly-owned subsidiary Gold Billion Global Limited (“GBL”), entered into a Shares Sale Agreement with Lamax Gold Limited (“LGL”), a company incorporated under the laws of the British Virgin Islands, in relation to acquisition of the remaining 15% of the issued and paid-up share capital of Champmark Sdn Bhd (“CSB”), a company incorporated under the laws of the Malaysia. Prior to this acquisition, GBL owned 85% equity in CSB. Upon completion of the acquisition, GBL would own the entire issued and paid-up share capital of CSB. Under the terms of the Shares Sale Agreement, the consideration for the acquisition shall be satisfied in full by the payment of Malaysia Ringgit MYR 150,000 upon the execution of the Shares Sale Agreement.

Item 9.01 Financial Statements and Exhibits

VERDE RESOURCES, INC. Exhibit
…
To view the full exhibit click here

About Verde Resources, Inc. (OTCMKTS:VRDR)

Verde Resources, Inc. is engaged in gold mining in Malaysia. The Company is undertaking natural mineral resource extraction management services. The Company conducts business operations in Pahang, Malaysia through its indirect subsidiary, Champmark Sdn Bhd (CSB). Its exploration and mining business is provided through contractual arrangements with CSB through its subsidiary, Gold Billion Global Limited (GBL). Its CSB, the variable interest entities (VIE) of GBL, sells gold minerals directly to the gold trading company in Malaysia. CSB holds the operating right to Merapoh Gold Mine (the Mine). The Mine is located in northern Pahang and in the middle of Malaysia’s gold metallogenic belt. It lies between the western and eastern tin belts and extends from Kelantan (Sungai Pergau and Sungai Galas) to Pahang (Merapoh, Kuala Lipis, Raub), Terengganu (Lubuk Mandi), Negri Sembilan and Johor (Gunung Ledang).

Story continues below

BIO-PATH HOLDINGS, INC. (NASDAQ:BPTH) Files An 8-K Regulation FD Disclosure

By
ME Staff 8-k
-

BIO-PATH HOLDINGS, INC. (NASDAQ:BPTH) Files An 8-K Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure.

On June 22, 2021, Bio-Path Holdings, Inc. (the “Company”) issued a press release titled, “Bio-Path Granted Key Mechanism of Action U.S. Patent for BP1003.” A copy of such press release is attached hereto as Exhibit 99.1.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number Description
99.1 Press Release dated June 22, 2021


BIO-PATH HOLDINGS INC Exhibit
EX-99.1 2 tm2120407d1_ex99-1.htm EXHIBIT 99.1   Exhibit 99.1       Bio-Path Granted Key Mechanism of Action U.S. Patent for BP1003   Provides Protection and Highlights Novelty of BP1003 to Inhibit STAT3 Expression in a Variety of Difficult to Treat Cancers   HOUSTON— June 22,…
To view the full exhibit click here

About BIO-PATH HOLDINGS, INC. (NASDAQ:BPTH)

Bio-Path Holdings, Inc. is a clinical and preclinical stage oncology focused antisense drug development company. The Company utilizes a technology that achieves systemic delivery for target specific protein inhibition for any gene product that is over-expressed in disease. Its drug delivery and antisense technology, DNAbilize, is a platform that uses P-ethoxy, a deoxyribonucleic acid backbone modification. Its lead drug candidate, Liposomal Grb2 (BP1001), targets the protein Growth factor receptor-bound protein 2 (Grb2). Its other liposome delivered antisense drug candidate, Liposomal Bcl2 (BP1002), targets the protein B-cell lymphoma 2 (Bcl2). BP1001 is in Phase II clinical trials for acute myeloid leukemia, and for blast phase and accelerated phase chronic myelogenous leukemia. BP1002 is intended to target the lymphoma and certain solid tumor markets. BP1001 is also in preclinical studies for solid tumors, including triple negative breast cancer and inflammatory breast cancer.

Story continues below

Evolving Systems, Inc. (NASDAQ:EVOL) Files An 8-K Submission of Matters to a Vote of Security Holders

By
ME Staff 8-k
-

Evolving Systems, Inc. (NASDAQ:EVOL) Files An 8-K Submission of Matters to a Vote of Security Holders

About Evolving Systems, Inc. (NASDAQ:EVOL)

Evolving Systems, Inc. is a provider of software solutions for service enablement, on-device activation and management of services for connected devices for network operators. The Company operates in two segments: license fees and services revenue, and customer support revenue. Its service activation solution, Tertio is used to activate voice, video and data services for wireless, wireline and cable network operators. Its Subscriber Identity Module (SIM) card activation solution, Dynamic SIM Allocation is used to allocate and assign resources to Mobile Network Operators devices that rely on SIM cards. Its Mobile Data Enablement solution provides a data consumption and policy management solution for wireless carriers and Mobile Virtual Network Operators that monitor the usage and consumption of data services. Its Total Number Management product is an automated database solution that enables operators to manage their telephone numbers, as well as other communication identifiers.

Story continues below

Rocky Mountain Chocolate Factory, Inc. (NASDAQ:RMCF) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

By
ME Staff 8-k
-

Rocky Mountain Chocolate Factory, Inc. (NASDAQ:RMCF) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02.

About Rocky Mountain Chocolate Factory, Inc. (NASDAQ:RMCF)

Rocky Mountain Chocolate Factory, Inc. is an international franchisor, confectionery manufacturer and retail operator. The Company’s subsidiary, U-Swirl International, Inc. (U-Swirl), franchises and operates soft-serve frozen yogurt stores. The Company operates through five segments: Franchising, Manufacturing, Retail Stores, U-Swirl operations and Other. The Company manufactures a range of chocolate candies and other confectionery products. The Company’s franchised/license system of retail stores features chocolate, frozen yogurt and other confectionary products. The Company also sells its candy in selected locations outside of its system of retail stores and licenses the use of its brand with certain consumer products. The Company’s products include a range of clusters, caramels, creams, mints and truffles. Its individual stores also offer over 15 fudges and other products prepared in the store. The Company uses chocolate, nut meats and other ingredients in its candies.

Story continues below

SPAR Group, Inc. (NASDAQ:SGRP) Files An 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

By
ME Staff 8-k
-

SPAR Group, Inc. (NASDAQ:SGRP) Files An 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 3.01.         Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

Resignation of Audit Committee Members from Board and its Committees

On June 9, 2021, in a letter to the Corporation, all three members of SGRP\’s Audit Committee, namely Mr. Arthur H. Baer, Mr. Igor Novgorodtsev, and Mr. Jeffrey A. Mayer (each a \”Resigning Independent Director\”), resigned from the Corporation\’s Board of Directors (the \”Board\”) and all of its committees, effective immediately (the \”Resignations\”). Management informed Nasdaq of the receipt of the Resignations on June 11, 2021. Please see SGRP\’s Current Report on Form 8-K reporting the Resignation as filed with the SEC on June 14, 2021 (the \”Resignation Report\”), and the Resignation Letter that was attached to the Resignation Report (the \”Resignation Letter\”).

Nasdaq Notice of Failure to Comply with its Board Independence and Audit Committee Composition Rules

As a result of the Resignations, SGRP received a notification letter from Nasdaq dated June 15, 2021 (the \”Nasdaq Deficiency Letter\”), stating that SGRP no longer complies with Nasdaq\’s majority independent director and audit committee requirements as set forth in Nasdaq Listing Rule 5605 (“Nasdaq Rules”).

In the Nasdaq Deficiency Letter, Nasdaq noted that a listed company normally has 45 calendar days to submit a detailed plan to regain compliance for non-compliance with the Nasdaq Rules. However, Nasdaq\’s Staff determined to give a shortened deadline for SGRP to submit its plan to regain compliance, until June 29, 2021, to its discretionary authority set forth in Listing Rule 5101.3. Please see Item 1A — Risk Factors — Risks of a Nasdaq Delisting and Penny Stock Trading in the Amended 2020 Annual Report.

If SGRP\’s plan to regain compliance with the Nasdaq Rules is accepted, Nasdaq\’s Staff can grant an extension of up to 180 calendar days from the date of the Nasdaq Deficiency Letter to permit and evidence such compliance.

The text of the Nasdaq Deficiency Letter is attached to and filed with this Current Report as Exhibit 17.1 hereto and is hereby incorporated by reference into this Current Report and made a part hereof. The descriptions of the Nasdaq Deficiency Letter in this Current Report are subject to and are qualified in their entirety by the full text of the Nasdaq Deficiency Letter.

For background on the ongoing disputes between the Company and its majority stockholders leading to the three independent director resignations, please see the Resignation Report.

Forward Looking Statements

This Current Report on Form 8-K (this \”Current Report\”) contains \”forward-looking statements\” within the \”safe harbor\” provisions of the Private Securities Litigation Reform Act of 1995, made by, or respecting, the Corporation and its subsidiaries (the \”Company\”), and this Current Report has been filed by the Corporation with the SEC. \”Forward-looking statements\” are defined in Section 27A of the Securities Act of 1933, as amended (the \”Securities Act\”), and Section 21E of the Securities Exchange Act of 1934, as amended (the \”Exchange Act\”), and other applicable federal and state securities laws, rules and regulations, as amended (together with the Securities Act and the Exchange Act, \”Securities Laws\”).

All statements (other than those that are purely historical) are forward-looking statements. Words such as \”may,\” \”will,\” \”expect,\” \”intend,\” \”believe,\” \”estimate,\” \”anticipate,\” \”continue,\” \”plan,\” \”project,\” or the negative of these terms or other similar expressions also identify forward-looking statements. Forward-looking statements made by the Corporation in this Current Report may include (without limitation) statements regarding: risks, uncertainties, cautions, circumstances and other factors (\”Risks\”); and plans, intentions, expectations, guidance, the novel coronavirus and COVID-19 pandemic on the Company\’s business, the Corporation\’s compliance with applicable Nasdaq director independence rules, the Company\’s cash flow or financial condition, the Company\’s cash flow, or the pursuit or achievement of the Company\’s corporate objectives.

 

 

You should carefully review and consider the Company\’s forward-looking statements (including all risk factors and other cautions and uncertainties) and other information made, contained or noted in or incorporated by reference into this Current Report, but you should not place undue reliance on any of them. The results, actions, levels of activity, performance, achievements or condition of the Company (including its affiliates, assets, business, clients, capital, cash flow, credit, expenses, financial condition, income, liabilities, liquidity, locations, marketing, operations, performance, prospects, sales, strategies, taxation or other achievement, results, Risks, trends or condition) and other events and circumstances planned, intended, anticipated, estimated or otherwise expected by the Company (collectively, \”Expectations\”), and our forward-looking statements (including all Risks) and other information reflect the Company\’s current views about future events and circumstances. Although the Company believes those Expectations and views are reasonable, the results, actions, levels of activity, performance, achievements or condition of the Company or other events and circumstances may differ materially from our Expectations and views, and they cannot be assured or guaranteed by the Company, since they are subject to Risks and other assumptions, changes in circumstances and unpredictable events (many of which are beyond the Company\’s control). In addition, new Risks arise from time to time, and it is impossible for the Company to predict these matters or how they may arise or affect the Company. Accordingly, the Company cannot assure you that its Expectations will be achieved in whole or in part, that it has identified all potential Risks, or that it can successfully avoid or mitigate such Risks in whole or in part, any of which could be significant and materially adverse to the Company and the value of your investment in the Company\’s common stock.

These forward-looking statements reflect the Company\’s Expectations, views, Risks and assumptions only as of the date of this Current Report, and the Company does not intend, assume any obligation, or promise to publicly update or revise any forward-looking statements (including any Risks or Expectations) or other information (in whole or in part), whether as a result of new information, new or worsening Risks or uncertainties, changed circumstances, future events, recognition, or otherwise.

Item 9.01.         Financial Statements and Exhibits.

(a) Exhibits:
17.1 Text of letter to SPAR Group, Inc. (\”SGRP\”), from the Nasdaq Stock Market, Inc. (\”Nasdaq\”), dated June 15, 2021, stating that SGRP no longer complies with Nasdaq\’s majority independent director and audit committee requirements as set forth in Nasdaq Listing Rule 5605 (as attached hereto and filed herewith).
 
 

SPAR Group, Inc. Exhibit
SEC.gov | Request Rate Threshold Exceeded html {height: 100%} body {height: 100%; margin:0; padding:0;} #header {background-color:#003968; color:#fff; padding:15px 20px 10px 20px;font-family:Arial,…
To view the full exhibit click here

About SPAR Group, Inc. (NASDAQ:SGRP)

Spar Group, Inc. is an international merchandising and marketing services company. The Company provides its merchandising and other marketing services to manufacturers, distributors and retailers across the world, primarily in mass merchandisers, office supply, grocery, drug store, independent, convenience, toy, home improvement and electronics stores. It operates through two segments: the Domestic Division and the International Division. The Domestic Division provides merchandising and marketing services, furniture and other product assembly services, audit services, and technology services to manufacturers, distributors and retailers in the United States. Those services are primarily performed in mass merchandisers, office supply, grocery, drug store, dollar and electronics stores. The International Division provides merchandising, marketing services and in-store event staffing through subsidiaries in Japan, Canada, South Africa, India, China, Australia, Mexico and Turkey.

Story continues below

VITALITY BIOPHARMA, INC. (OTCMKTS:VBIO) Files An 8-K Other Events

By
ME Staff 8-k
-

VITALITY BIOPHARMA, INC. (OTCMKTS:VBIO) Files An 8-K Other Events
Item 8.01

On June 21, 2021, Vitality Biopharma, Inc. (the “Company”) posted on the Company’s website (www.vitality.bio) a letter from the Company’s Chief Executive Officer, Michael Cavanaugh, to the Company’s shareholders. A copy of the letter is filed as Exhibit 20.1 to this Current Report on Form 8-K.

20.1 Letter from Michael Cavanaugh to the Company’s Shareholders


Vitality Biopharma, Inc. Exhibit
EX-20.1 2 ex20-1.htm   Exhibit 20.1     To the Shareholders of Vitality Biopharma,…
To view the full exhibit click here

About VITALITY BIOPHARMA, INC. (OTCMKTS:VBIO)

Vitality Biopharma, Inc., formerly Stevia First Corp., is engaged in the development of cannabinoid prodrug pharmaceuticals. The Company unlocks the power of cannabinoids for the treatment of serious neurological and inflammatory disorders. Its product pipeline includes cannabosides, VITA-100 and VITA-210. Cannabosides are cannabinoid glycoside prodrugs. VITA-100 is an oral cannabinoid formulation containing cannabosides that is being developed for treatment of inflammatory bowel disease, epilepsy, schizophrenia, and other disorders. VITA-210 is a cannabinoid glycoside prodrug being developed primarily for treatment of pain and muscle spasticity in multiple sclerosis and in rare white matter disorders. The Company’s facilities include laboratories and a manufacturing suite for good manufacturing practices (GMPs) production, which will be used for pharmaceutical-grade production of products to be tested in clinical trials.

Story continues below

TONIX PHARMACEUTICALS HOLDING CORP. (NASDAQ:TNXP) Files An 8-K Regulation FD Disclosure

By
ME Staff 8-k
-

TONIX PHARMACEUTICALS HOLDING CORP. (NASDAQ:TNXP) Files An 8-K Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure.

Tonix Pharmaceuticals Holding Corp. (the “Company”) updated its investor presentations, which are used to conduct meetings with investors, stockholders and analysts and at investor conferences, and which the Company intends to place on its website, which may contain nonpublic information. Copies of the presentations are filed as Exhibits 99.01 and 99.02 hereto and incorporated herein by reference.  

The information in this Item 7.01 of this Current Report on Form 8-K, including Exhibits 99.01 and 99.02 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the United States Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference in any filing under the United States Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

99.01 Corporate Presentation by the Company for June 2021
99.02 Abbreviated Corporate Presentation by the Company for June 2021


Tonix Pharmaceuticals Holding Corp. Exhibit
EX-99.01 2 ex99-01.htm CORPORATE PRESENTATION   Tonix Pharmaceuticals Holding Corp. 8-K   Exhibit 99.01     © 2021 Tonix Pharmaceuticals Holding Corp. 1 June 2021 Version P0304 6 – 22 – 2021 (Doc 0852) Investor Presentation NASDAQ:TNXP     © 2021 Tonix Pharmaceuticals Holding Corp. 2 Cautionary Note on Forward – Looking Statements Certain statements in this presentation regarding strategic plans,…
To view the full exhibit click here

Story continues below

BIOCARDIA, INC. (OTCMKTS:BCDA) Files An 8-K Other Events

By
ME Staff 8-k
-

BIOCARDIA, INC. (OTCMKTS:BCDA) Files An 8-K Other Events
Item 8.01 Other Events.

On June 22, 2021, BioCardia, Inc. (the “Company”) issued a press release announcing that data demonstrating the high CD34+ cell dosing being achieved in the ongoing pivotal CardiAMP Heart Failure Trial will be presented at the virtual European Society of Cardiology Heart Failure Annual Meeting 2021. A copy of the press release is attached hereto as Exhibit 99.1 to this current report on Form 8-K and is incorporated herein by reference.

Item 9.01   Financial Statements and Exhibits.

(d) Exhibits

 
 

BioCardia, Inc. Exhibit
EX-99.1 2 ex_258884.htm EXHIBIT 99.1 ex_258884.htm   Exhibit 99.1     FOR IMMEDIATE RELEASE     BioCardia to Present CardiAMP Cell Therapy Clinical Trial Data at European Society of Cardiology Heart Failure 2021   Cell Therapy Platform Demonstrates High Dose CD34+ Cell Performance Characteristics in Patients with Ischemic Heart Failure.   June 22,…
To view the full exhibit click here

About BIOCARDIA, INC. (OTCMKTS:BCDA)

BioCardia, Inc., formerly Tiger X Medical, Inc., is a clinical-stage regenerative medicine company. The Company is engaged in developing therapeutics for cardiovascular diseases. The Company’s lead therapeutic candidate is the CardiAMP Cell Therapy System (CardiAMP). It focuses on the Phase III trial for CardiAMP in ischemic systolic heart failure. The Company also offers CardiALLO Cell Therapy System (CardiALLO), an allogeneic off the shelf mesenchymal stem cell product candidate from other donors. It focuses on the Phase II trial for CardiALLO for the treatment of ischemic systolic heart failure. The Company focuses on various fields of autologous and allogeneic cell-based therapies to manage the lives of patients with cardiovascular conditions. CardiAMP is a therapeutic treatment that includes a companion diagnostic. It consists of a cell potency screening test, a point of care cell processing platform and a biotherapeutic delivery system.

Story continues below
1...192021...14,629Page 20 of 14,629

EDITOR PICKS

POPULAR POSTS

POPULAR CATEGORY

© Market Exclusive 2019